Loading...
 
Back to the list
Mediterr J Rheumatol 2022;33(3):380-3
Article Links
Panniculitis as the Transformed Cutaneous Manifestation of Refractory Dermatomyositis with Successful Management with Tofacitinib
Upendra Rathore1, Neha Nigam2, Amita Aggarwal1, Latika Gupta1
Authors Information
  1. Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
  2. Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

L Gupta, U Rathore, A Aggarwal, N Nigam

Keywords: panniculitis, dermatomyositis, tofacitinib
References
  1. Santos-Briz A, Calle A, Linos K, Semans B, Carlson A, Sangüeza OP, et al. Dermatomyositis panniculitis: a clinicopathological and immunohistochemical study of 18 cases. J Eur Acad Dermatol Venereol 2018;32(8):1352–9.
  2. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982 Feb;25(2):126–39.
  3. Chairatchaneeboon M, Kulthanan K, Manapajon A. Calcific panniculitis and nasopharyngeal cancer-associated adult-onset dermatomyositis: a case report and literature review. Springerplus 2015;4:201.
  4. Girouard SD, Velez NF, Penson RT, Massarotti EM, Vleugels RA. Panniculitis associated with dermatomyositis and recurrent ovarian cancer. Arch Dermatol 2012 Jun;148(6):740–4.
  5. Galimberti F, Kooistra L, Li Y, Chatterjee S, Fernandez AP. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis. Clin Exp Dermatol 2018 Dec;43(8):906–12.
  6. Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford) 2019 01;58(6):1011–5.